| |  Online-Ressource |
|---|
| Verfasst von: | Allgäuer, Michael [VerfasserIn]  |
|---|
| | Budczies, Jan [VerfasserIn] |
|---|
| | Christopoulos, Petros [VerfasserIn] |
|---|
| | Endris, Volker [VerfasserIn] |
|---|
| | Lier, Amelie [VerfasserIn] |
|---|
| | Rempel, Eugen [VerfasserIn] |
|---|
| | Volckmar, Anna-Lena [VerfasserIn] |
|---|
| | Kirchner, Martina [VerfasserIn] |
|---|
| | Winterfeld, Moritz von [VerfasserIn] |
|---|
| | Leichsenring, Jonas [VerfasserIn] |
|---|
| | Neumann, Olaf [VerfasserIn] |
|---|
| | Fröhling, Stefan [VerfasserIn] |
|---|
| | Penzel, Roland [VerfasserIn] |
|---|
| | Thomas, Michael [VerfasserIn] |
|---|
| | Schirmacher, Peter [VerfasserIn] |
|---|
| | Stenzinger, Albrecht [VerfasserIn] |
|---|
| Titel: | Implementing tumor mutational burden (TMB) analysis in routine diagnostics |
|---|
| Titelzusatz: | a primer for molecular pathologists and clinicians |
|---|
| Verf.angabe: | Michael Allgäuer, Jan Budczies, Petros Christopoulos, Volker Endris, Amelie Lier, Eugen Rempel, Anna-Lena Volckmar, Martina Kirchner, Moritz von Winterfeld, Jonas Leichsenring, Olaf Neumann, Stefan Fröhling, Roland Penzel, Michael Thomas, Peter Schirmacher, Albrecht Stenzinger |
|---|
| E-Jahr: | 2018 |
|---|
| Jahr: | Aug 15, 2018 |
|---|
| Umfang: | 13 S. |
|---|
| Teil: | volume:7 |
|---|
| | year:2018 |
|---|
| | number:6 |
|---|
| | pages:703-715 |
|---|
| | extent:13 |
|---|
| Fussnoten: | Gesehen am 05.05.2020 |
|---|
| Titel Quelle: | Enthalten in: Translational Lung Cancer Research |
|---|
| Ort Quelle: | [S.l.], 2012 |
|---|
| Jahr Quelle: | 2018 |
|---|
| Band/Heft Quelle: | 7(2018), 6, Seite 703-715 |
|---|
| ISSN Quelle: | 2226-4477 |
|---|
| Abstract: | Tumor mutational burden (TMB) is a new biomarker for prediction of response to PD-(L)1 treatment. Comprehensive sequencing approaches (i.e., whole exome and whole genome sequencing) are ideally suited to measure TMB directly. However, as their applicability in routine diagnostics is currently limited by high costs, long turnaround times and poor availability of fresh tissue, targeted next-generation sequencing (NGS) of formalin-fixed and paraffin-embedded (FFPE) samples appears to be a more feasible and straight-forward approach for TMB approximation, which can be seamlessly integrated in already existing diagnostic workflows and pipelines. In this work, we provide an overview of the clinical implications of TMB testing and highlight key parameters including pre-analysis, analysis and post-analytical steps that influence and shape TMB approximation by panel sequencing. Collectively, the data will not only serve as a field guide and state of the art knowledge source for molecular pathologists who consider implementation of TMB measurement in their lab, but also enable clinicians in understanding the specific parameters influencing TMB test results and reporting. |
|---|
| DOI: | doi:10.21037/tlcr.2018.08.14 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext ; Verlag: https://doi.org/10.21037/tlcr.2018.08.14 |
|---|
| | Volltext: http://tlcr.amegroups.com/article/view/23935 |
|---|
| | DOI: https://doi.org/10.21037/tlcr.2018.08.14 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| K10plus-PPN: | 1697246389 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Implementing tumor mutational burden (TMB) analysis in routine diagnostics / Allgäuer, Michael [VerfasserIn]; Aug 15, 2018 (Online-Ressource)
